A plain language summary of the CEPHEUS study of daratumumab plus bortezomib, lenalidomide, and dexamethasone for people with newly diagnosed multiple myeloma who are not expected to receive a stem cell transplant
This is an author's accepted manuscript due to be published by Taylor & Francis in Future Oncology 07/10/2025, available online at https://doi.org/10.1080/14796694.2025.2560134. The accepted manuscript may differ from the final published version.
Authors
- Christopher P. Venner (ORCID: https://orcid.org/0000-0003-4701-4285)
- Saad Z. Usmani (ORCID: https://orcid.org/0000-0002-5484-8731)
- Marc Justin Braunstein (ORCID: https://orcid.org/0000-0002-0859-7257)
- Luděk Pour (ORCID: https://orcid.org/0000-0002-6274-7009)
- Ângelo Maiolino (ORCID: https://orcid.org/0000-0003-0140-9548)
- Thierry T.F. Facon (ORCID: https://orcid.org/0000-0001-7705-8460)
- Jodi Carey
- Hiroyuki Takamatsu (ORCID: https://orcid.org/0000-0001-9515-0017)
- Jessica Vermeulen
- Sebastian Grosicki (ORCID: https://orcid.org/0000-0003-2644-1050)
- Richard G. Carson (ORCID: https://orcid.org/0000-0002-1190-2814)
- Nizar Jacques Bahlis (ORCID: https://orcid.org/0000-0001-7353-7034)
- Tahamtan Ahmadi (ORCID: https://orcid.org/0009-0007-5031-3792)
- Yael Chava Cohen (ORCID: https://orcid.org/0000-0002-9061-7287)
- Meral Beksaç (ORCID: https://orcid.org/0000-0003-1797-8657)
- Aurore Perrot (ORCID: https://orcid.org/0000-0003-0131-8689)
- Sonja Zweegman (ORCID: https://orcid.org/0000-0002-5011-1820)
- Katherine Chastain
- Maria Krevvata
- Wojciech Maciej Legiec (ORCID: https://orcid.org/0000-0003-3093-5248)
- Supratik Basu (ORCID: https://orcid.org/0000-0003-2206-4796)
- Weiping Liu (ORCID: https://orcid.org/0000-0002-0367-1411)
- Jianping Wang (ORCID: https://orcid.org/0000-0002-4882-8021)
- Mehmet Turgut (ORCID: https://orcid.org/0000-0002-1036-0232)
- Josep Maria Martí (ORCID: https://orcid.org/0000-0001-9452-1277)
- Morio Matsumoto (ORCID: https://orcid.org/0000-0001-9791-0139)
- Lorena Lopez-Masi
- Kenshi Suzuki
- Cyrille Hulin
- Melissa Rowe
- Vânia Hungria
Institutions
- University of Wolverhampton (GB)
- Universidade Federal do Rio de Janeiro (BR)
- BC Cancer Agency (CA)
- Johnson & Johnson (United States) (US)
- Memorial Sloan Kettering Cancer Center (US)
- Université Toulouse III - Paul Sabatier (FR)
- University of British Columbia (CA)
- University of Alberta (CA)
- Tel Aviv University (IL)
- Medical University of Silesia (PL)
- Université Fédérale de Toulouse Midi-Pyrénées (FR)
- Ondokuz Mayıs University (TR)
- Tel Aviv Sourasky Medical Center (IL)
- Spinal Cord Injury BC (CA)
- Centre Hospitalier Universitaire de Lille (FR)
- Kettering University (US)
- NYU Langone Health (US)
- University Hospital Mútua de Terrassa (ES)
- University Hospital Brno (CZ)
- Japanese Red Cross Medical Center (JP)
- Kanazawa University Hospital (JP)
- São Germano Oncologia (BR)
- Alberta Cancer Foundation (CA)
- Hôpital Cardiologique du Haut-Lévêque (FR)
- Princeton Satellite Systems (United States) (US)
- Lublin Oncology Center (PL)
- Mútua Terrassa (ES)
- Johnson & Johnson (Israel) (IL)
- National Hospital Organization (JP)
- Johnson & Johnson (United Kingdom) (GB)
- National Education and Research Network (BR)
- Liv Hospital (TR)
- The Royal Wolverhampton NHS Trust (GB)
- Johnson & Johnson (Netherlands) (NL)
- Universidade Federal do Estado do Rio de Janeiro (BR)
- Vrije Universiteit Amsterdam (NL)
Publication Details
- Journal
- Future Oncology
- Published
- 2025-10-07
- DOI
- https://doi.org/10.1080/14796694.2025.2560134
- Primary Topic
- Multiple Myeloma Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00